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Background-—Onset of postoperative atrial ﬁbrillation (POAF) is a common and costly complication of heart surgery despite major
improvements in surgical technique and quality of patient care. The etiology of POAF, and the ability of clinicians to identify and
therapeutically target high-risk patients, remains elusive.
Methods and Results-—Myocardial tissue dissected from right atrial appendage (RAA) was obtained from 244 patients undergoing
cardiac surgery. Reactive oxygen species (ROS) generation from multiple sources was assessed in this tissue, along with total
glutathione (GSHt) and its related enzymes GSH-peroxidase (GPx) and GSH-reductase (GR). Monoamine oxidase (MAO) and NADPH
oxidase were observed to generate ROS at rates 10-fold greater than intact, coupled mitochondria. POAF risk was signiﬁcantly
associated with MAO activity (Quartile 1 [Q1]: adjusted relative risk [ARR]=1.0; Q2: ARR=1.8, 95% conﬁdence interval [CI]=0.84 to 4.0;
Q3: ARR=2.1, 95% CI=0.99 to 4.3; Q4: ARR=3.8, 95% CI=1.9 to 7.5; adjusted Ptrend=0.009). In contrast, myocardial GSHt was inversely
associated with POAF (Quartile 1 [Q1]: adjusted relative risk [ARR]=1.0; Q2: ARR=0.93, 95% conﬁdence interval [CI]=0.60 to 1.4; Q3:
ARR=0.62, 95%CI=0.36 to 1.1; Q4: ARR=0.56, 95%CI=0.34 to 0.93; adjusted Ptrend=0.014). GPx alsowas signiﬁcantly associated with
POAF; however, a linear trend for risk was not observed across increasing levels of the enzyme. GR was not associated with POAF risk.
Conclusions-—Our results show that MAO is an important determinant of redox balance in human atrial myocardium, and that this
enzyme, in addition to GSHt and GPx, is associated with an increased risk for POAF. Further investigation is needed to validate
MAO as a predictive biomarker for POAF, and to explore this enzyme’s potential role in arrhythmogenesis. ( J Am Heart Assoc.
2014;3:e000713 doi: 10.1161/JAHA.113.000713)
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S ubstantial improvements in patient outcomes followingcardiac surgery have occurred over the past decade due
to developments in technology and quality of care. However,
there are a number of signiﬁcant and costly post-operative
complications associated with cardiac surgery, including post-
operative atrial ﬁbrillation (POAF). Even with anti-arrhythmic
therapy and improvements in myocardial protection, the
incidence of POAF remains at 25% to 40%.1 POAF typically
occurs within the ﬁrst 2 to 3 days after surgery and results in
prolonged hospital length of stay. Patients with POAF have a
doubled risk of cardiovascular mortality and a greater
incidence of symptomatic hypotension, stroke, and other
arrhythmias than patients without POAF.2,3 Findings from the
Virginia Cardiac Surgery Quality Initiative, a state-wide cost
analysis of all cardiac surgeries from 2004 to 2007, estimated
that POAF increased total treatment costs by $12 000/
patient.
Important gaps remain in understanding the etiology of
POAF and why certain patients are more likely to have this
complication. Systemic inﬂammation (generated primarily
from extracorporeal circulation) and increased atrial reactive
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oxygen species (ROS) are believed to be causal factors. Both
of these stressors potentially impair atrial contraction, disrupt
myoﬁbrillar energetics, and reduce the atrial effective refrac-
tory period.4,5 ROS-producing enzyme NADPH oxidase is up-
regulated6,7 and oxidative stress is more persistent8 in
patients with POAF than those that remain in sinus rhythm.
The results of these studies support an association between
ROS in human atrium and POAF.
Another factor contributing to POAF is the increased
sympathetic tone and levels of circulating catecholamines
following surgery.9,10 The importance of the association
between circulating catecholamines and POAF is compounded
by the intra- and post-operative use of high-dose catechol-
amines (eg, dopamine, dobutamine) as inotropic agents, a
standard-of-care practice which continues despite the known
association between inotropic support and POAF.1,11 The 2
primary enzymes responsible for metabolizing catecholamines
are monoamine oxidase (MAO) and catechol O-methyltrans-
ferase (COMT). COMT is highly expressed in kidney and liver
tissue, but expressed at low levels in the heart.12 MAO, which
is present in the outer mitochondrial membrane, is respon-
sible for oxidative deamination of catecholamines (eg,
epinephrines, dopamine, serotonin) and the generation of
H2O2, NH4
+, and reactive aldehydes.13,14 Furthermore, this
enzyme is involved in mood disorders and is the target of
several pharmaceutical agents (MAO inhibitors) acting on this
pathway. Recently, increased MAO activity has been observed
to play a causal role in cardiac dysfunction during pressure
overload due to oxidative stress.15,16
In the current study, we sought to determine the overall
contribution of MAO as a source of ROS in human
myocardium. ROS generation by MAO, NADPH oxidase,
and mitochondrial electron transport system (mito-ETS) was
assessed in myocardial tissue dissected from right atrial
appendage (RAA) obtained from patients undergoing cardiac
surgery. Given the putative association between catechol-
amine overload, oxidative stress, and POAF, we hypothe-
sized that MAO activity in the atrium and ROS produced by
this enzyme may be associated with POAF. Additionally, we
postulated that an association exists between POAF,
myocardial glutathione (GSHt), and related enzymes GSH-
peroxidase (GPx) and GSH-reductase (GR), since this is the
primary antioxidant system present in mammalian cells and
tissues.
Methods
Patient Enrollment and Inclusion/Exclusion
Criteria
Approval for this study was granted by the Institutional
Review Board of the Brody School of Medicine at East
Carolina University. A total of 244 patients undergoing
primary, non-emergent coronary artery bypass graft
(CABG) or CABG/valve surgery between January 2009 and
December 2012 were enrolled. Patients with severely
enlarged atria (>4.0 cm diameter), history of arrhythmia,
prior cardiac surgery, left ventricular ejection fraction (LVEF)
<30%, and history of anti-arrhythmic medication were
excluded from this study.
Atrial Tissue Collection and Processing
Following median sternotomy, but prior to institution of
cardiopulmonary bypass, a sample of the right atrial append-
age (RAA) was resected and immediately rinsed in ice-cold
Buffer X.17 The sample was then blotted on gauze to remove
excess buffer, trimmed of the epicardial layer, and frozen in
liquid N2. This method ensured that all samples obtained were
predominantly myocardium and rapidly processed and frozen
(<90 seconds from time of removal) to minimize protein and
mRNA degradation. In some cases viable atrial myocardium
was transferred to the laboratory and used for preparation of
permeabilized myoﬁbers (PmFBs) and analysis of mitochon-
drial function.
Permeabilized Fiber Preparation
Portions of this technique have been described elsewhere,17
but have been adapted for application in human cardiac
muscle and for speciﬁc measurements made in this study.
After RAA tissue harvest, myocardium was removed and
placed in ice-cold Buffer X, containing (in mmol/L: 7.23
K2EGTA, 2.77 CaK2EGTA, 20 Imidazole, 20 Taurine, 5.7 ATP,
14.3 PCr, 6.56 MgCl26H2O, 50 MES; pH 7.1). Muscle was
then cut into strips 4 to 6 mm L92 to 3 mm wide and
placed in a solution of Buffer X containing 3 mg/mL
collagenase Type I (Sigma-Aldrich), and incubated for 30 to
45 minutes at 4°C. Fiber bundles were then carefully
trimmed of vascular and connective tissue, separated along
their longitudinal axis, and permeabilized for 30 minutes in
Buffer X+50 lg/mL saponin at 4°C. We used 30 lg/mL
saponin if patient was female, for reasons described
elsewhere.18 Following permeabilization, myoﬁber bundles
(PmFBs) were washed in ice-cold Buffer Z containing (in
mmol/L): 110 K-MES, 35 KCl, 1 EGTA, 5 K2HPO2, 3
MgCl26H2O, and 5 mg/mL BSA (pH 7.4, 295 mOsm) and
remained in Buffer Z on a rotator at 4°C until analysis
(<2 hours). We have observed that PmFBs exhibit a very
strong Ca2+-independent contraction that is temperature
sensitive and can occur even at 4°C,19 therefore, 20 lmol/L
Blebbistatin (Sigma-Aldrich) was added to the wash buffer, in
addition to the respiration medium during experiments, to
prevent contraction as previously described.
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Measurement of Mitochondrial H2O2 Emission in
Cardiac PmFBs
All mitochondrial H2O2 measurements were performed at
37°C. H2O2 coming from mito-ETS as a result of palmitoyl-
L-carnitine, glutamate, and succinate oxidation was deter-
mined in PmFB’s with 100 lmol/L ADP, 5 mmol/L
glucose, and 1 U/mL hexokinase present to keep the
mitochondria in a permanent, submaximal phosphorylat-
ing state (ie, most physiological).20,21 H2O2 emission rate
was determined in real time by continuous monitoring of
Amplex Red oxidation in presence of horseradish peroxi-
dase (1 U/mL) and superoxide dismutase (25 U/mL) using
a spectroﬂuorometer (Photon Technology Instruments,
Birmingham, NJ,) equipped with a thermo-jacketed cuvette
chamber.
MAO and NADPH Oxidase Activity
Myocardial samples frozen in liquid N2 were homogenized in
10X (wt./vol) TEE buffer containing (in mmol/L: 10 Tris
base, 1 EDTA, 1 EGTA, and 0.5% Tween-20), using a glass
grinder (Kimble Chase). All enzyme activity and glutathione
assays were performed on the same day as the protein
extraction. We have empirically determined that glutathione
and enzyme activity must be assessed immediately in
protein extractions to obtain accurate results, and that
freezing samples or keeping them at 4°C overnight will
cause dramatic loss of content and activity. H2O2 generation
from MAO and NADPH oxidase was determined in real time
by continuous monitoring of Amplex Red oxidation in
presence of horseradish peroxidase (1 U/mL) and superox-
ide dismutase (25 U/mL) using a spectroﬂuorometer (Horiba
Jobin Yvon) equipped with a thermo-jacketed cuvette
chamber maintained at 37°C. MAO activity was determined
by continuous monitoring of clorgyline-sensitive H2O2 pro-
duction supported by 1 mmol/L Tyramine or 2 lmol/L
Norepinephrine, as previously described.22 NADPH oxidase
activity was determined by continuous monitoring of apocy-
nin-sensitive H2O2 production supported by 0.5 mmol/L
NADPH.23
GSHt, GPx, and GR Activity
All enzyme activity and glutathione assays were performed
on the same day as the protein extraction. Total glutathi-
one measurements were performed as described previ-
ously24,25 using a modiﬁed Tietze method.26 GR activity in
myocardial tissue was measured in TEE buffer containing
1 mmol/L GSSG and 0.5 mmol/L NADPH, where activity
was calculated from the linear decrease in NADPH
absorbance with time.27 Glutathione peroxidase (GPx)
activity was determined in TEE buffer containing 1 mmol/
L GSH, 100 mU/mL glutathione reductase enzyme,
0.5 mmol/L NADPH. The reaction is initiated with a
nominal amount of tert-Butyl-Hydroperoxide and the activity
of GPx was calculated from the linear decrease in NADPH
absorbance with time.28
Determination of POAF
Postoperatively, patients’ heart rate and rhythm were contin-
uously monitored with telemetry until discharge. POAF was
deﬁned by a sustained episode of atrial ﬁbrillation lasting
≥1 minute, or for any length of time requiring intervention for
hemodynamic compromise.
Statistical Analysis
Categorical variables were reported as frequency and
percentage while continuous variables were reported as
meanstandard deviation, median, and interquartile range.
Variables not previously categorized were divided into
quartiles prior to statistical analysis. Quartile categoriza-
tion is advantageous because it limits the inﬂuence of
outliers and allows for the assessment of trend across
categories.
Statistical signiﬁcance of group comparisons for categor-
ical variables was determined using Fisher exact and chi-
square (v2) procedures and for continuous variables was
determined using the Deuchler-Wilcoxon method. Relative
risk and 95% conﬁdence intervals were computed using log-
binomial or robust Poisson regression. P values for trend were
computed using a likelihood ratio test (or score test when
convergence was not achieved). Assays were performed using
a missing by design sampling strategy. The iterative expec-
tation-maximization (EM) algorithm was used to impute
missing values.29–31 The relative imputation efﬁciency ranged
from 96% to 99% (variance inﬂation: MAO=0.38, GSHt=0.02,
GPx=0.15, GR=0.54; fraction missing information:
MAO=0.29, GSHt=0.02, GPx=0.14, GR=0.37). Patients with
and without missing data did not differ by key demographic
characteristics (ie, age, sex, race; Hochberg adjusted
P>0.05).32 Furthermore, a complete-case analysis was per-
formed and it did not substantively change the results of the
study. The multivariable models included variables that have
been previously reported to be associated with POAF,
regardless of their statistical signiﬁcance in our dataset.
These included age, sex, race, diabetes, hypertension, ACEI
use, ARB use, statin use, and CPBT.7,33–36 Statistical signif-
icance was deﬁned as P<0.05. SAS Version 9.3 was used for
all analyses.
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Results
Analysis of Major ROS Sources in Human Atrial
Myocardium
An assessment of 3 major ROS sources in atrial myocardium
was performed from RAA biopsies of 12 individual patients
(demographic and clinical characteristics of these 12 patients
is provided in Table 1). Rates of H2O2 production in the
myocardial tissue homogenate was conﬁrmed to be derived
from MAO and NADPH oxidase based on the sensitivity to
their inhibitors clorgyline and apocynin, respectively (Fig-
ure 1A). H2O2 production derived from the mito-ETS was
driven by oxidation of substrates as they were individually
titrated into the respiration medium containing the PmFBs
(Figure 1A). Total rates of H2O2 production from these 3
sources were individually quantiﬁed and combined within
each of the 12 patients (Figure 1B). The rate of H2O2
originating from mito-ETS was determined to be at least 10-
fold lower than either MAO or NADPH oxidase alone. As
previously reported by our group, diabetic patients had
signiﬁcantly higher rates of H2O2 from mito-ETS compared
with non-diabetic patients.20,21
Patient Characteristics, Biochemical Markers,
and Relationship to POAF
A total of 80 (33%) patients developed POAF. Patients with
POAF were older and presented more frequently with
hypertension than those without POAF (Table 2). Additionally,
they experienced longer CPBT. Mean MAO levels were
signiﬁcantly higher among patients with POAF (P<0.0001)
and a linear trend across quartile levels was observed
(Ptrend<0.0001), with the incidence of POAF being the highest
in quartile 4 compared with quartile 1 (Figure 2). POAF was
not associated with GSHt, GPx, and GR (Figures 3 and 4B and
4C) in the univariable analysis. In multivariable analysis, MAO
remained statistically signiﬁcant after adjusting for age, sex,
race, diabetes, hypertension, ACEI/ARB use, statin use, and
CPBT (Ptrend=0.009, Table 3). A statistically signiﬁcant linear
trend also was observed for GSHt in multivariable analysis
(Ptrend=0.014).
Discussion
Several reports have documented the inverse association of
POAF and b-blocker use, illustrating the underlying etiologic
role of catecholamines and excessive sympathetic dis-
charge.37,38 Others have used prophylactic amiodarone,39
sotalol,40 magnesium,41 and statins,42 all of which were
successful at reducing the incidence of POAF to varying
degrees; however, all patients were treated regardless of
POAF status. These studies illustrate the importance of
investigating biological factors that may predispose patients
to POAF.
The ﬁndings of this study demonstrate for the ﬁrst time
that MAO is a major source of ROS in human atrial
myocardium, and its activity varies across a 50-fold range
among patients. It also provides evidence that atrial MAO
activity serves as an independent predictor of POAF and lends
further support to the current theory that redox imbalance (ie,
oxidative stress) in atrial myocardium is a signiﬁcant factor
in the etiology of POAF, particularly with respect to our
Table 1. Clinical and demographic information speciﬁc for patients in Figure 1.
Pt # Age Sex Race Diabetes HbA1c HF POAF Tobacco COPD Prior MI HTN
1 79 F AA Y 6.9 N N N N N Y
2 63 F C Y 10 N N Y Y Y Y
3 67 F AA Y 7.2 Y Y Y N N Y
4 62 F AA N – N N N N N Y
5 60 F C Y 9.2 N N N N N Y
6 69 F AA N – N N Y N N Y
7 47 M C N – N N N N N N
8 56 M C N – N N N N N Y
9 52 M AA N – N N Y N N Y
10 44 M C N – N N Y N Y Y
11 58 M C N – N Y N N N Y
12 52 M C Y 8.9 N Y Y N Y Y
Absent values (–) for glycated hemoglobin (HbA1c) indicate that levels were within normal range (4.5% to 5.9%) for that particular patient (Pt). AA indicates African-American; C, Caucasian;
COPD, history of chronic obstructive pulmonary disease; HF, history of heart failure; HTN, history of hypertension; MI, myocardial infarction; POAF, post-operative atrial ﬁbrillation.
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myocardial GSHt-related data. Furthermore, the results
collectively integrate a number of perioperative factors known
to contribute to the etiology of POAF (eg, catecholamine
overload and oxidative stress).
Investigation into the etiology of POAF has largely focused
on systemic inﬂammation and oxidative stress in the post-
operative period. Redox modiﬁcations of ion channels and
proteins have been observed to directly impact cardiomyocyte
electrical43,44 and mechanical45 function and has been
implicated in the early stages of electrical remodeling which
accompanies the onset of AF.46 Inﬂammation is intercon-
nected with myocardial oxidative stress.4,5 Circulating cyto-
kines and electrophilic lipids increase strain on antioxidant
mechanisms in cardiomyocytes, a system already burdened
with buffering oxidants originating from endogenous sources
(eg, MAO, NADPH oxidase, and mitochondria) (Figure 1). The
most important buffer of ROS in mammalian cells and tissue
is GSH, which is converted to its oxidized form (GSSG) by GPx
in the presence of hydroperoxides, and recycled back to its
reduced form by NADPH-dependent GR. The GSH/GSSG
(reduced/oxidized) redox couple is considered to be the key
indicator of cellular redox environment.47 Also important to
cellular/tissue redox environment is total amount of GSH
(GSHt), deﬁned as the additive amount of free GSH and GSSG.
A decrease in GSHt potentially increases a cell’s susceptibility
to the adverse outcomes associated with oxidative stress
(eg, oxidative modiﬁcations of proteins, lipids, and DNA).
Our ﬁndings that GSHt and GPx are inversely correlated with
POAF (Figures 3 and 4) suggests that a greater antioxidant
capacity should lead to lower incidence of POAF because of a
greater buffering of ROS during the postoperative period.
Clinical trials have shown that anti-inﬂammatory/antioxidant
therapies lead to a decreased incidence of POAF.48,49 For
example, preoperative n-3 polyunsaturated fatty acids (PU-
FAs) and concentrated antioxidant supplementation have
been observed to enhance anti-inﬂammatory/antioxidant
capacity in atrial myocardium at the cellular level.50 A
follow-up clinical trial with this therapy led to a substantial
decrease in POAF.51 Use of n-3 PUFAs alone as prophylactic
therapy to mitigate incidence of POAF has led to mixed
results. For example, the omega-3 fatty acids for prevention of
postoperative atrial ﬁbrillation (OPERA) trial showed that a
very high dose (8 to 10 g/day) of n-3 PUFAs for 2 to 3 days
preoperatively did not reduce the incidence of POAF.52
Nevertheless, use of n-3 PUFAs as prophylactic therapy for
arrhythmia and other cardiovascular diseases remains a viable
therapeutic option due to the pleiotropic, beneﬁcial effects of
these fatty acids in the heart.
Mitochondria, as a consequence of their intracellular
volume and density, are considered the predominant source
of intracellular ROS in myocardium.53 However, the total ROS
that escapes (ie, ROS emission) from the mitochondria is
minimized by the reducing environment within the matrix of
this organelle in addition to its redox enzyme network.54,55
Figure 1. Comparative analysis of major ROS sources in human atrial myocardium. A, Representative
H2O2 production traces from NADPH oxidase (blue), MAO (red), and mito-ETS (black dash) in RAA tissue
obtained from one individual patient. PmFBs were used for determining H2O2 from mito-ETS, while
homogenate was used for NADPH oxidase and MAO. Substrates were added to cuvette where indicated.
Apocynin and Clorgyline are administered where indicated to conﬁrm the source of H2O2 production to be
NADPH oxidase and MAO, respectively. In (B) are the quantiﬁed rates from each of these 3 sources in RAA
tissue obtained from 12 individual patients. MAO indicates monoamine oxidase; mito-ETS, mitochondrial
electron transport system; NADPH, b-Nicotinamide adenine dinucleotide phosphate hydrate; PmFBs,
permeabilized myoﬁbers; RAA, right atrial appendage; ROS, reactive oxygen species.
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Table 2. Patient and Operative Characteristics Stratiﬁed by Postoperative Rhythm Class and Univariable Relative Risk for POAF
(N=244)
Variables
POAF
n (%)
POSR
n (%) P Value
Univariable
RR (95% CI)
Overall 80 (33) 164 (67) — —
Demographics/comorbidities
Age
MeanSD 668.7 6210 0.0019 —
Median (IQR) 67 (14) 62 (16)
Q1 (≤56) 10 (13) 54 (33) 0.0045 Referent
Q2 (56 to 64) 20 (25) 39 (24) 2.2 (1.1 to 4.2)
Q3 (64 to 71) 23 (29) 37 (23) 2.5 (1.3 to 4.7)
Q4 (>71) 27 (34) 34 (21) 2.8 (1.5 to 5.3)
Ptrend=0.0008
Sex
Female 14 (18) 41 (25) 0.19 Referent
Male 66 (83) 123 (75) 1.4 (0.84 to 2.2)
Race
White 69 (86) 132 (80) 0.27 Referent
Black 11 (14) 32 (20) 1.3 (0.78 to 2.3)
Diabetes
No 50 (63) 84 (51) 0.096 Referent
Yes 30 (38) 80 (49) 0.73 (0.50 to 1.06)
Hypertension
No 7 (9) 34 (21) 0.019 Referent
Yes 73 (91) 130 (79) 2.1 (1.05 to 4.2)
BMI*
MeanSD 305.7 306.2 0.74 —
Median (IQR) 30 (7.4) 30 (7.2)
Q1 (≤26) 23 (29) 39 (24) 0.69 Referent
Q2 (26 to 30) 17 (22) 43 (26) 0.76 (0.46 to 1.3)
Q3 (30 to 33) 22 (27) 40 (25) 0.96 (0.60 to 1.5)
Q4 (>33) 18 (23) 42 (26) 0.81 (0.49 to 1.3)
Ptrend=0.60
Smoking
No 59 (74) 107 (65) 0.18 Referent
Yes 21 (26) 57 (35) 0.76 (0.50 to 1.2)
COPD
No 60 (75) 136 (83) 0.14 Referent
Yes 20 (25) 28 (17) 1.4 (0.92 to 2.02)
Prior stroke
No 74 (93) 154 (94) 0.68 Referent
Yes 6 (8) 10 (6) 1.2 (0.60 to 2.2)
Continued
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Table 2. Continued
Variables
POAF
n (%)
POSR
n (%) P Value
Univariable
RR (95% CI)
Prior MI
No 45 (56) 75 (46) 0.12 Referent
Yes 35 (44) 89 (54) 0.75 (0.52 to 1.08)
HF
No 79 (99) 155 (95) 0.089† Referent
Yes 1 (1) 9 (5) 0.30 (0.046 to 1.9)
Ejection fraction*
MeanSD 5411 5314 0.30 —
Median (IQR) 58 (10) 54 (15)
Q1 (≤48) 17 (22) 52 (32) 0.066 Referent
Q2 (48 to 55) 19 (24) 42 (26) 1.3 (0.72 to 2.2)
Q3 (55 to 62) 25 (31) 28 (17) 1.9 (1.2 to 3.2)
Q4 (>62) 19 (24) 42 (26) 1.3 (0.72 to 2.2)
Ptrend=0.15
CAD severity*
1-vessel 3 (4) 11 (7) 0.20 Referent
2-vessel 15 (19) 44 (27) 1.2 (0.40 to 3.5)
3-vessel 62 (77) 109 (67) 1.7 (0.61 to 4.7
Ptrend=0.079
Left main disease
No 65 (81) 135 (82) 0.84 Referent
Yes 15 (19) 29 (18) 1.0 (0.66 to 1.7)
Preoperative Medications
Beta-blockers
No 12 (15) 28 (17) 0.68 Referent
Yes 68 (85) 136 (83) 1.1 (0.67 to 1.9)
ACEI/ARBS
No 70 (88) 128 (78) 0.076 Referent
Yes 10 (13) 36 (22) 0.61 (0.34 to 1.1)
Statins
No 18 (23) 33 (20) 0.67 Referent
Yes 62 (78) 131 (80) 0.91 (0.60 to 1.4)
Intraoperative Characteristics
CPB
No 3 (4) 10 (6) 0.44 Referent
Yes 77 (96) 154 (94) 1.4 (0.53 to 4.0)
CPBT (min)
MeanSD 12033 11037 0.012 —
Median (IQR) 115 (37) 104 (48)
Q1 (≤87) 9 (12) 49 (32) 0.0092 Referent
Q2 (87 to 108) 22 (29) 37 (24) 2.4 (1.2 to 4.8)
Q3 (108 to 134) 26 (34) 35 (23) 2.7 (1.4 to 5.4)
Q4 (>134) 20 (26) 33 (21) 2.4 (1.2 to 4.9)
Continued
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This potentially explains our observation that H2O2 originating
from mito-ETS was markedly lower than from either MAO or
NADPH oxidase alone (Figure 1). ROS derived from NADPH
oxidase in atrial myocardium, and downstream ROS (eg,
peroxynitrite and reactive aldehydes) have been shown to be
signiﬁcantly correlated with POAF.6,7 Our ﬁndings further
support the clinical importance of ROS-generating enzymes in
atrial tissue and provide novel evidence that ROS derived from
MAO may be a key determinant of myocardial redox balance
in the postoperative period.
Table 2. Continued
Variables
POAF
n (%)
POSR
n (%) P Value
Univariable
RR (95% CI)
Biomarkers
MAO*
MeanSD 28431987 17251130 <0.0001 —
Median (IQR) 2608 (2038) 1691 (1286)
Q1 (≤1344) 8 (10) 54 (33) <0.0001 Referent
Q2 (1344 to 2035) 15 (19) 44 (27) 2.0 (0.90 to 4.3)
Q3 (2035 to 2820) 19 (23) 42 (25) 2.4 (1.1 to 5.1)
Q4 (>2820) 38 (47) 24 (15) 4.8 (2.4 to 9.3)
Ptrend<0.0001
GSHt*
MeanSD 196.0 206.5 0.15 —
Median (IQR) 18 (7.6) 20 (7.9)
Q1 (≤16) 24 (30) 36 (22) 0.36 Referent
Q2 (16 to 20) 22 (28) 39 (24) 0.90 (0.57 to 1.4)
Q3 (20 to 23) 17 (21) 45 (27) 0.69 (0.41 to 1.1)
Q4 (>23) 17 (22) 44 (27) 0.70 (0.42 to 1.2)
Ptrend=0.099
GPX*
MeanSD 175.6 176.9 0.42 —
Median (IQR) 17 (6.6) 16 (9.4)
Q1 (≤12) 13 (16) 48 (29) 0.024 Referent
Q2 (12 to 17) 25 (31) 37 (22) 1.9 (1.1 to 3.3)
Q3 (17 to 21) 26 (32) 34 (21) 2.0 (1.2 to 3.6)
Q4 (>21) 16 (20) 45 (27) 1.2 (0.65 to 2.3)
Ptrend=0.46
GR*
MeanSD 4.72.5 4.72.6 0.42 —
Median (IQR)
Q1 (≤3.8) 21 (26) 40 (24) 0.64 Referent
Q2 (4.8) 21 (26) 41 (25) 0.98 (0.60 to 1.6)
Q3 (5.6) 22 (28) 38 (23) 1.1 (0.66 to 1.7)
Q4 (>5.6) 16 (20) 45 (27) 0.76 (0.44 to 1.3)
Ptrend=0.40
Tests of statistical signiﬁcance (chi-square for categorical variables, Deuchler-Wilcoxon for continuous variables). ACEI indicates angiotensin converting enzyme inhibitor; ARB, angiotensin
receptor blocker; BMI, body mass index; CAD, coronary artery disease; CI, conﬁdence interval; COPD, chronic obstructive pulmonary disease; CPBT, cardiopulmonary bypass time; GPX,
glutathione peroxidase; GR, glutathione reductase; GSHt, total glutathione; HF, heart failure; IQR, interquartile range; MAO, monoamine oxidase; MI, myocardial infarction; POAF,
postoperative atrial ﬁbrillation; POSR, postoperative sinus rhythm; Q1, ﬁrst quartile; Q2, second quartile; Q3, third quartile; Q4, fourth quartile; RR, relative risk; SD, standard deviation.
*Missing values imputed using EM algorithm (n=10 simulations).
†Statistical signiﬁcance computed using Fisher’s Exact. Ptrend computed using likelihood ratio trend test.
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While MAO is an enzyme physically tethered to the outer
mitochondrial membrane, MAO-derived ROS typically is not
considered to be “mitochondrial ROS.” Our ﬁndings support a
paradigm shift in the way this enzyme is viewed within the
context of cellular redox balance. The wide range in MAO
activity (50-fold) across patients is a signiﬁcant feature of
our ﬁndings (Figure 2). Theoretically, the expression and
activity of cardiac MAO should reﬂect sympathetic tone;
however, there is considerable variation in promoter activity
and transcriptional control of MAO genes in humans.56 This
may explain the underlying variation in enzyme activity seen in
our patient cohort. Conceivably, high levels of catecholamines
in the postoperative period may lead to increased concentra-
tions inside cardiomyocytes by neuronal monoamine trans-
porters in the sarcolemmal membrane.12 Thus, in patients
where MAO activity is high (Q3 and Q4, Figure 2), MAO-
derived ROS may in turn be increased, leading to oxidative
stress and potentially triggering POAF. In the remodeled
myocardium, where ﬁbrosis and altered ion channel expression
are present, oxidative stress and inﬂammation only comprise
a portion of the arrhythmogenic substrate. Accordingly,
Table 3. Multivariate Analysis of Independent Risk Factors
Predictive of POAF*
Models ARR 95% CI
MAO†
Q1 (≤1344) Referent
Q2 (1344 to 2035) 1.8 (0.83 to 4.0)
Q3 (2035 to 2820) 2.1 (0.99 to 4.3)
Q4 (>2820) 3.8 (1.9 to 7.5)
Ptrend=0.009
GSH†
Q1 (≤16) Referent
Q2 (16 to 20) 0.93 (0.60 to 1.4)
Q3 (20 to 23) 0.62 (0.36 to 1.1)
Q4 (>23) 0.56 (0.34 to 0.93)
Ptrend=0.014
GPX†
Q1 (≤12) Referent
Q2 (12 to 17) 1.9 (1.1 to 3.3)
Q3 (17 to 21) 2.4 (1.4 to 4.2)
Q4 (>21) 1.4 (0.75 to 2.7)
Ptrend=0.21
ARR indicates adjusted relative risk; CI, conﬁdence interval; GPX, glutathione peroxidase;
GSH, glutathione; MAO, monoamine oxidase; POAF, postoperative atrial ﬁbrillation; Q1,
ﬁrst quartile; Q2, second quartile; Q3, third quartile; Q4, fourth quartile.
*Models adjusted for age, sex, race, diabetes, angiotensin converting enzyme inhibitor
and angiotensin receptor blocker use, statin use, and hypertension.
†Missing values imputed using EM algorithm (n=10 simulations). Ptrend computed using
score trend test.
Figure 2. MAO activity in atrial myocardium and incidence of
POAF. All rates of MAO activity from entire cohort of patients
recruited for this study are shown (1 circle=1 patient). Quartiles of
pooled data were generated, and univariable analysis performed
with POAF as the outcome variable using Poisson regression. Each
quartile is delineated with color shading to illustrate the risk of
POAF within that particular quartile (Green=<15%, Yellow=15% to
30%, Orange=30% to 40%, Red=>60%). Within each quartile, POAF
incidence=number of patients in that particular quartile experienc-
ing POAF. RR=relative risk, with 95% conﬁdence interval (CI). MAO
indicates monoamine oxidase; POAF, post-operative atrial
ﬁbrillation.
Figure 3. Total GSH (GSHt) in atrial myocardium and incidence of
POAF. Data shown in this ﬁgure is GSHt for the entire cohort of
patients recruited for this study. Quartiles of pooled data were
generated, and univariable analysis performed with POAF as the
outcome variable using Poisson regression. Each quartile is
delineated with color shading to illustrate the risk of POAF within
that particular quartile (Red=>40%, Yellow=15% to 30%,
Orange=30% to 40%). Within each quartile, POAF incidence=num-
ber of patients in that particular quartile experiencing POAF.
RR=relative risk, with 95% conﬁdence interval (CI). GSHt indicates
total glutathione; POAF, post-operative atrial ﬁbrillation.
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therapeutic strategies to mitigate POAF need to account for
all of these possibilities.
Our study is strengthened by its prospective and system-
atic data collection. Additionally, biomarkers were obtained
from myocardial tissue and reﬂect local cardiac versus serum
levels. However, several limitations should be noted. Only the
right atrial myocardium was collected in this study, and this
may not be the best anatomic site to represent cardiac
remodeling and oxidative stress pathways in the heart, given
the known importance of the left atrium as a site of
arrhythmogenesis. Moreover, studies have shown that as
the pathology of AF progresses, a gradient of cardiac
remodeling occurs starting in the left atrium and ending in
the right atrium.57 The temporality and spatial heterogeneity
of this remodeling may be missed by capturing only the right
atrium. However, because this patient cohort did not have any
history of arrhythmia or cardiac surgery, it is unlikely that any
remodeling that may exist is due to atrial arrhythmia.
Saturating concentrations of substrate (eg, Tyramine,
NADPH, glutamate, etc) were used to measure enzyme
activities in our assays. This rarely exists in vivo. However,
the use of saturating substrate concentration was appropriate
because the objective was to compare the maximal capacity
for ROS generation and scavenging from myocardial enzymes.
Biopsies were obtained at a single point in time; therefore it
was not possible to determine the temporality of biomarker
levels. Limited longitudinal information was available in our
dataset. We were unable to determine the dose, duration, and
frequency of b-blocker use prior to surgery for each patient.
Furthermore, our sample size was small and residual
confounding may have been present.
In conclusion, our study suggests that MAO is a major ROS
source in human atrial myocardium and is an important
biomarker for POAF, providing clinicians with the ability to
predict which patients are predisposed to this postoperative
complication. Advanced knowledge of POAF risk will enable
appropriate prophylactic treatment to be initiated at the time
of surgery, potentially leading to reduced hospital stay and
healthcare costs associated with this complication. Additional
investigation is needed to elucidate the role of MAO in
arrhythmogenesis and to validate our ﬁndings in other
populations and disease processes.
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